Fresenius SE & Co. KGaA Q3 2026 Earnings Recap

Shares rose 6.3% after Fresenius raised its full-year core EPS outlook, now expecting growth in the upper half of its 10%–15% range at constant currency. The company also lifted its group EBIT margin indication to above 11.5%.

Key Takeaways

• Q3 continued the first-half trend: earnings grew faster than sales, while free cash flow more than doubled year over year.
• The group reported a year-to-date EBIT margin of 11.7% and said returns continued to improve, reaching the highest ROIC in the decade.
• Kabi reported broad-based growth; the Ivenix infusion system’s U.S. installed base exceeded 30,000 units.
• Biopharma demand for Tyenne in the U.S. continues to exceed current supply, but Tyenne moved from preferred to nonpreferred status on the UNH Optum formulary.